Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection

PharmacoEconomics

Volumn 29, Issue 12, 2011, Pages 1063-1073

  Hung, Hui Fang ^a   Chen, Hsiu Hsi ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cost effectiveness; Cost utility; Hepatitis B; Hepatitis B immune globulin; Hepatitis B vaccine; Infants; Lamivudine; Pregnancy third trimester.

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PLACEBO; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ACTIVE IMMUNIZATION; ARTICLE; CHRONIC HEPATITIS; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG COST; DRUG EFFICACY; DRUG SCREENING; ECONOMIC EVALUATION; HEALTH CARE COST; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HIDDEN MARKOV MODEL; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LIVER CELL CARCINOMA; META ANALYSIS; MOTHER; NEWBORN INFECTION; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TAIWAN; VERTICAL TRANSMISSION;

ANTIVIRAL AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS;

EID: 81255176943     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11586470-000000000-00000     Document Type: Article

References (63)

1. Stevens CE, Beasley RP, Tsui J, et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975 Apr 10; 292 (15): 771-4
2. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. JAMA 1985 Mar 22-29; 253 (12): 1740-5 (Pubitemid 15141106)
3. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276: 906-8
4. del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, the Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997 Oct; 15 (15): 1624-30 (Pubitemid 27445742)
5. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004 Oct 7; 351 (15): 1521-31
6. McGowan JP, Shah SS. Prevention of perinatal HIV transmission during pregnancy. J Antimicrob Chemother 2000 Nov; 46 (5): 657-68
7. Li X, Yang Y, Hou H, et al. Interruption of HBV intrauterine transmission: A clinical study. World J Gastroenterol 2003 Jul; 9 (7): 1501-3 (Pubitemid 36992341)
8. van Zonneveld M, van Nunen A, Niesters H, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003 Jul; 10 (4): 294-7 (Pubitemid 36801916)
9. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: Amulticentre, randomized, double-blind, placebocontrolled study. J Viral Hepat 2009 Feb; 16 (2): 94-103
10. Gilks WR, Richardson S, Spiegelhalter DJ, et al. Markov Chain Monte Carlo in practice. New York: Chapman and Hall, 1996
11. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996 Sep 18; 276 (11): 906-8
12. Lin DB, Wang HM, Lee YL, et al. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine 1998 Oct; 16 (17): 1683-7
13. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983 Nov 12; 2 (8359): 1099-102 (Pubitemid 14242389)
14. Edmunds WJ,Medley GF, NokesDJ, et al. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 1996 Oct; 117 (2): 313-25 (Pubitemid 26345241)
15. Hsu HY, Chang MH, Chen DS, et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986 Apr; 18 (4): 301-7
16. Ip HM, Lelie PN, Wong VC, et al. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989 Feb 25; 1 (8635): 406-10 (Pubitemid 19059152)
17. Lee SD, Lo KJ, Wu JC, et al. Prevention of maternal-infant hepatitis B virus transmission by immunization: The role of serum hepatitis B virus DNA. Hepatology 1986 May-Jun; 6 (3): 369-73
18. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985 Apr; 151 (4): 599-603 (Pubitemid 15102154)
19. Shah N, Ostrow D, Altman N, et al. Evolution of acute hepatitis B in homosexual men to chronic hepatitis B: prospective study of placebo recipients in a hepatitis B vaccine trial. Arch Intern Med 1985 May; 145 (5): 881-2 (Pubitemid 15033253)
20. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigenpositive hepatitis in Greek adults. Gastroenterology 1987 Jun; 92 (6): 1844-50 (Pubitemid 17072231)
21. Dupuy JM, Frommel D, Alagille D. Severe viral hepatitis type B in infancy. Lancet 1975 Jan 25; 1 (7900): 191-4
22. Redeker AG. Viral hepatitis: clinical aspects. Am J Med Sci 1975 Jul-Aug; 270 (1): 9-16
23. Karvountzis GG, RedekerAG, PetersRL. Long termfollowup studies of patients surviving fulminant viral hepatitis. Gastroenterology 1974 Nov; 67 (5): 870-7
24. Edmunds WJ,Medley GF, Nokes DJ, et al. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993 Aug 23; 253 (1337): 197-201 (Pubitemid 23262603)
25. McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990 May; 150 (5): 1051-4 (Pubitemid 20155330)
26. Kocak N, Ozen H, Yuce A, et al. Long-term follow-up of hepatitis B virus carriers with normal transaminases levels. Turk J Pediatr 1998 Jul-Sep; 40 (3): 365-72 (Pubitemid 128564098)
27. Nishida S, Tada R, Nishiwaki T, et al. Seven-year follow-up studies on asymptomatic HBsAg carriers. Sangyo Igaku 1982 May; 24 (3): 253-64 (Pubitemid 12025425)
28. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular arcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. AmJ Epidemiol 1997 Jun 1; 145 (11): 1039-47
29. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann. Intern. Med. 2001 Nov 6; 135 (9): 759-68 (Pubitemid 33051260)
30. Alward WL, McMahon BJ, Hall DB, et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985 Apr; 151 (4): 604-9 (Pubitemid 15102155)
31. ShermanM, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995 Aug; 22 (2): 432-8
32. Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology 1991 Apr; 13 (4): 627-31
33. Crook PD, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol 2003 Feb; 32 (1): 118-24 (Pubitemid 36503487)
34. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988; 8 (3): 493-6
35. Fattovich G, Brollo L, GiustinaG, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991 Mar; 32 (3): 294-8
36. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients. J Hepatol 1998 Jun; 28 (6): 930-8 (Pubitemid 28275969)
37. Chen DS, Sheu JC, Shung JL. A prospective study on the occurrence of hepatocellular carcinoma in patients with cirrhosis, chronic hepatitis and asymptomatic HBsAg carriers [abstract]. Symposium on Epidemiology and Clinical Trials 1985 Jun 10-12: 1036-49
38. De Groote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978 Jun; 19 (6): 510-3 (Pubitemid 8363910)
39. Lo KJ, Tong MJ, Chien MC, et al. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis 1982 Aug; 146 (2): 205-10 (Pubitemid 12009785)
40. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: A prospective study. Gastroenterology 1986 Feb; 90 (2): 263-7
41. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995 Jan; 21 (1): 77-82
42. D'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986 May; 31 (5): 468-75 (Pubitemid 16085568)
43. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003 Feb; 23 (1): 47-58 (Pubitemid 36254662)
44. Marcellin P, Castelnau C, Martinot-Peignoux M, et al. Natural history of hepatitis B. Minerva Gastroenterol Dietol 2005 Mar; 51 (1): 63-75 (Pubitemid 44251920)
45. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16-year population-based study. Hepatology 2000 Oct; 32 (4 Pt 1): 842-6
46. Hutton DW, Tan D, So SK, et al. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann. Intern. Med. 2007 Oct 2; 147 (7): 460-9 (Pubitemid 351664518)
47. Bloom BS, Hillman AL, Fendrick AM, et al. A reappraisal of hepatitis B virus vaccination strategies using cost-effectivenessanalysis. Ann. Intern. Med. 1993; 118 (4): 298-306 (Pubitemid 23046389)
48. Fendrick AM, Lee JH, LaBarge C, et al. Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: Estimating cost-effectiveness using decision analysis. Arch Pediatr AdolescMed 1999 Feb; 153 (2): 126-36 (Pubitemid 29070320)
49. Ginsberg GM, Shouval D. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. J Epidemiol Community Health 1992; 46 (6): 587-94
50. Da Villa G, Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 1999 Mar 26; 17 (13-14): 1734-8 (Pubitemid 29138909)
51. Shepherd J, Jones J, Takeda A, et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation. Health Technol Assess 2006; 10: iii-iv, xi-xiv, 1-183
52. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: A costeffectiveness analysis. Ann. Intern. Med. 2005; 142: 821-31 (Pubitemid 40664041)
53. Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health 2003; 51: 227-36 (Pubitemid 37159655)
54. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 2002 Jun 1; 30 (2): 200-15 (Pubitemid 34664418)
55. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996 Nov 27; 62 (10): 1456-62 (Pubitemid 26404668)
56. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis [published erratum appears in Lancet 1997 Feb 1; 349 (9048): 364]. Lancet 1996 Nov 2; 348 (9036): 1212-5
57. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.NEngl J Med 1998 Jul 9; 339 (2): 61-8 (Pubitemid 28304879)
58. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 Oct 21; 341 (17): 1256-63 (Pubitemid 29489740)
59. Tuon FF, Guastini CMdF, Boulos MIC. Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis. Braz J Infect Dis 2008 Aug; 12 (4): 263
60. Soylu AR, Dö kmeci G, Tezel A, et al. Lamivudine-induced acute pancreatitis in a patient with decompensated Hbvrelated chronic liver disease. J Clin Gastroenterol 2004 Feb; 38 (2): 134 (Pubitemid 38134152)
61. BienvenuL,Burel F, HofmanV, et al. Arare etiology of hepatic steatosis associated with lactic acidosis: The toxicity of antiviral nucleoside analogues. Ann Pathol 2001 Apr; 21 (2): 160-3 (Pubitemid 32428469)
62. Nelson M, Azwa A, Sokwala A, et al. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS 2008 Jul 11; 22 (11): 1374-6
63. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003 Mar 15; 36 (6): 687-96 (Pubitemid 36337972)